Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- Acronyms PRESERVED-HF
- 05 Nov 2018 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
- 05 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
- 31 Aug 2018 Biomarkers information updated